中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月13日星期天
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2022, Vol. 29 Issue (19): 53-55转60    
  临床研究 本期目录 | 过刊浏览 | 高级检索 |
脑电双频指数、神经元特异性烯醇化酶联合监测对颅脑外伤患者预后的评估价值
钱武强1 2      赵   平1 2      时小芬1 2      汤建磊1 2      崔微艳1 2▲
1.江苏大学附属武进医院,江苏常州   213000;
2.徐州医科大学武进临床学院重症医学科,江苏常州   213000
Evaluation value of combined monitoring of bispectral index and neuron-specific enolase in the prognosis of patients with traumatic brain injury
QIAN Wuqiang1 2   ZHAO Ping1 2   SHI Xiaofen1 2   TANG Jianlei1 2   CUI Weiyan1 2▲
1. Wujin Hospital Affiliated to Jiangsu University, Jiangsu Province, Changzhou   213000, China;
 2. Department of Critical Medicine, Wujin Clinical College of Xuzhou Medical University, Jiangsu Province, Changzhou   213000, China
全文: PDF (707 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探析脑电双频指数(BIS)、神经元特异性烯醇化酶(NSE)联合监测在颅脑外伤患者预后中的诊断价值。方法 选取2020年3月至2021年7月江苏大学附属武进医院收治的60例颅脑外伤患者作为研究对象,根据格拉斯哥预后评分(GOS)分为预后良好组(n=23)和预后不良组(n=37)。所有患者均接受BIS监测以及NSE水平检测。比较两组患者的BIS值、NSE水平,分析BIS值、NSE指标与预后评分的相关性以及BIS值、NSE指标对颅脑外伤预后的预测价值。结果 预后良好组的BIS水平高于预后不良组,而NSE水平低于预后不良组,差异有统计学意义(P<0.05)。相关性分析结果显示,BIS值与预后GOS评分呈正相关(r=0.712,P=0.001),NSE水平与预后GOS评分呈负相关(r=-0.606,P=0.001)。BIS值、NSE指标联合监测(AUC=0.93)预测颅脑外伤预后不良的敏感度、特异度高于单一BIS值(AUC=0.81)、NSE指标(AUC=0.77)监测。结论 BIS值与血清NSE水平均可反映颅脑外伤患者的预后质量,BIS值越低,NSE指标越高,预后质量越差,且联合监测更有利于提高监测敏感度及特异度,值得临床推广。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
钱武强
赵平
时小芬
汤建磊
崔微艳
关键词 颅脑外伤脑电双频指数神经元特异性烯醇化酶预后评估    
Abstract:Objective To explore the diagnostic value of combined monitoring of bispectral index (BIS) and neuron-specific enolase (NSE) in the prognosis of patients with traumatic brain injury. Methods A total of 60 patients with raumatic brain injury from March 2020 to July 2021 in Wujin Hospital Affiliated to Jiangsu University were selected as the research subjects. According to the Glasgow outcome scale (GOS), they were divided into the good prognosis group (n=23) and the poor prognosis group (n=37). All patients received BIS monitoring and NSE level detection. The BIS value and NSE level of the two groups of patients were compared, and the correlation between BIS value and NSE index and prognostic score, as well as the predictive value of BIS value and NSE index on the prognosis of traumatic brain injury were analyzed. Results The BIS level in the good prognosis group was higher than that in the poor prognosis group, while the NSE level in the good prognosis group was lower than that in the poor prognosis group, and the differences were statistically significant (P<0.05). The results of correlation analysis showed that the BIS value was positively correlated with the prognostic GOS score (r=0.712, P=0.001), and the NSE level was negatively correlated with the prognostic GOS score (r=-0.606, P=0.001). Combined monitoring of BIS value and NSE index (AUC=0.93) had higher sensitivity and specificity than those of single BIS value (AUC=0.81) and NSE index (AUC=0.77) in predicting poor prognosis of traumatic brain injury. Conclusion Both BIS value and serum NSE level can reflect the prognosis quality of patients with traumatic brain injury. The lower the BIS value, the higher the NSE index, the worse the prognosis quality, and the combined monitoring is more conducive to improving the monitoring sensitivity and specificity, which is worthy of clinical promotion.
Key wordsTraumatic brain injury    Bispectral index    Neuron-specific enolase    Prognosis evaluation
    
通讯作者: ▲通讯作者   
引用本文:   
钱武强; 赵平; 时小芬; 汤建磊; 崔微艳. 脑电双频指数、神经元特异性烯醇化酶联合监测对颅脑外伤患者预后的评估价值[J]. 中国当代医药, 2022, 29(19): 53-55转60.
QIAN Wuqiang; ZHAO Ping; SHI Xiaofen; TANG Jianlei; CUI Weiyan. Evaluation value of combined monitoring of bispectral index and neuron-specific enolase in the prognosis of patients with traumatic brain injury. 中国当代医药, 2022, 29(19): 53-55转60.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2022/V29/I19/53
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载